Kory James Wentworth Sells 5,089 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth sold 5,089 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $13.00, for a total transaction of $66,157.00. Following the completion of the transaction, the chief financial officer owned 132,898 shares of the company’s stock, valued at $1,727,674. This trade represents a 3.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kory James Wentworth also recently made the following trade(s):

• On Tuesday, March 10th, Kory James Wentworth sold 11,388 shares of Entrada Therapeutics stock. The shares were sold at an average price of $13.02, for a total value of $148,271.76.
• On Wednesday, March 4th, Kory James Wentworth sold 7,988 shares of Entrada Therapeutics stock. The stock was sold at an average price of $12.25, for a total transaction of $97,853.00.

Entrada Therapeutics Stock Performance

Entrada Therapeutics stock opened at $12.98 on Friday. Entrada Therapeutics, Inc. has a fifty-two week low of $4.93 and a fifty-two week high of $13.65. The firm’s fifty day moving average price is $11.28 and its 200-day moving average price is $8.89. The stock has a market cap of $496.87 million, a P/E ratio of -3.75 and a beta of -0.12.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Thursday, February 26th. The company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.32) by $0.38. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $7.41 million. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. On average, analysts predict that Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts have weighed in on TRDA shares. Guggenheim raised Entrada Therapeutics to a “strong-buy” rating in a report on Wednesday, February 11th. Oppenheimer assumed coverage on shares of Entrada Therapeutics in a research note on Wednesday, January 28th. They issued an “outperform” rating and a $21.00 price objective on the stock. Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Entrada Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Entrada Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $18.50.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Millennium Management LLC increased its holdings in Entrada Therapeutics by 391.2% in the third quarter. Millennium Management LLC now owns 836,609 shares of the company’s stock worth $4,852,000 after buying an additional 666,287 shares during the last quarter. Citadel Advisors LLC raised its position in shares of Entrada Therapeutics by 234.5% during the 3rd quarter. Citadel Advisors LLC now owns 335,741 shares of the company’s stock worth $1,947,000 after buying an additional 235,384 shares in the last quarter. Baker BROS. Advisors LP grew its stake in shares of Entrada Therapeutics by 4.3% in the 4th quarter. Baker BROS. Advisors LP now owns 5,072,730 shares of the company’s stock worth $52,148,000 after purchasing an additional 206,911 shares during the last quarter. Qube Research & Technologies Ltd raised its position in shares of Entrada Therapeutics by 115.3% during the third quarter. Qube Research & Technologies Ltd now owns 287,873 shares of the company’s stock worth $1,670,000 after purchasing an additional 154,143 shares during the period. Finally, BNP Paribas Financial Markets boosted its position in shares of Entrada Therapeutics by 4,767.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 148,212 shares of the company’s stock valued at $860,000 after purchasing an additional 145,167 shares during the period. Hedge funds and other institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.